Clozaril

April 30^th, 2025 Wednesday

12:30 - 13:45 GMT

You are invited to a Treatment-Resistant Schizophrenia Promotional Webinar

Viatris is delighted to invite you to our upcoming TRS webinar featuring Professor Ramalingam Chithiramohan, Consultant Psychiatrist, Birmingham and Solihull Mental Health Foundation Trust. The presentation will focus on a treatment-resistant schizophrenia masterclass.

A speaker Q&A session will follow the presentation and a “Certificate of Attendance” will be available after the webinar.

Speaker

Professor Ramalingam Chithiramohan

Consultant Psychiatrist, Birmingham and Solihull NHS Foundation Trust

Agenda

12.15 onwards

Webinar platform opens for registered delegates

12.30
12.35

Welcome and introduction

Umran Mohammed, Therapy Development Manager, Viatris Mental Health UK

12.35
13.30

Treatment-resistant schizophrenia: a masterclass for healthcare professionals

Professor Ramalingam Chithiramohan

13.30
13.45

Q&A Session

Professor Ramalingam Chithiramohan

13.45

Webinar closes

First Name*

FirstName is Required

Last Name*

Last Name is Required

Email*

Email Address is required Email is not in proper format

Phone*

Phone is required Phone number should not exceed 20 digits

Profession*

Profession is Required

Role*

Please select role

Specialty*

Please select specialty

Workplace Name*

Workplace Name is Required Invalid Workplace Name [Only Letters and Digits are Acceptable]

Workplace Postcode*

Workplace Postcode is Required Postcode must contain a space and be a combination of letters and numbers in capital letters

Area of Interest*

Please select Area of interest

This is a promotional meeting, organised and funded by Viatris. Product and brand names are mentioned.

By clicking ‘Submit’ I confirm I am a Healthcare Professional residing in the United Kingdom and I have read and understand Viatris’ Privacy Policy and Terms of Use. I understand I will be receiving related information and reminders for this webinar.

I agree that Viatris Inc., its affiliates and subsidiaries (“Viatris”) may use my personal data to communicate and provide me with scientific and pharmaceutical information such as email on healthcare related products, events, or surveys (promotional & non promotional). I understand and acknowledge all information processed by Viatris is handled in accordance with local privacy laws and may be captured and processed in countries outside of the jurisdiction in which it was collected. I understand that I can withdraw my consent at any time. The withdrawal of consent will not affect the lawfulness of processing based on consent before its withdrawal.

Yes No

Please, select "Yes" or "No" to proceed with registration

UK-CLZ-2025-00026 April 2025

Prescribing Information

Clozaril^®/Clozapine Mylan is indicated in treatment-resistant schizophrenic patients and in schizophrenia patients who have severe, untreatable neurological adverse reactions to other antipsychotic agents, including atypical antipsychotics. Treatment resistance is defined as a lack of satisfactory clinical improvement despite the use of adequate doses of at least two different antipsychotic agents, including an atypical antipsychotic agent, prescribed for adequate duration.

You are now leaving a Viatris website